References
- 1. Al-Najeem HT, Al-Dujaili ANG. Assessment of bone morphogentic protein receptor 2 level in pulmonary arterial hypertension disease. Res J Pharm Tech. 2017;10(8):2614-8.
- 2. Al-Najeem HT, Al-Dujaili ANG. Assessment of Germlin-1 level in pulmonary arterial hypertension disease. Res J Pharm Tech. 2017;10(11):3803-6.
- 3. Paulin R, Meloche J, Bonnet S. STAT3 signaling in pulmonary arterial hypertension. JAKSTAT 2012;1(4):223-33.
- 4. Meloche J, Pflieger A, Vaillancourt M, Graydon C, Provencher S, Bonnet S. MiRNAs in PAH: Biomarker, therapeutic target or both? Drug Discov Today. 2014;19(8):1264-9.
- 5. Sylvester JT, Shimoda LA, Aaronson PI, Ward JPT. Hypoxic pulmonary vasoconstriction. Physiol Rev. 2012;92(1):367-520.
- 6. Wang J, Fu X, Yang K, Jiang Q, Chen Y, Jia J, et al. Hypoxia inducible factor-1-dependent up-regulation of BMP4 mediates hypoxia-induced increase of TRPC expression in PASMCs. Cardiovasc Res. 2015;107(1):108-18.
- 7. Zhang Y, Wang Y, Yang K, Tian L, Fu X, Wang Y, et al. BMP4 increases the expression of TRPC and basal [Ca2+]i via the p38MAPK and ERK1/2 pathways independent of BMPRII in PASMCs. PLoS One. 2014;9(12):e112695.
- 8. Song B., Jin H., Yu X., Zhang Z., Yu H., Ye J., et al.: Angiotensin-converting enzyme 2 attenuates oxidative stress and VSMC proliferation via the JAK2/STAT3/SOCS3 and profilin-1/MAPK signaling pathways. Regul Pept. 2013;185,44-51.
- 9. Boucherat O, Bonnet S. NOGGIN: A new therapeutic target for PH? Focus on “Noggin inhibits hypoxia-induced proliferation by targeting store-operated calcium entry and transient receptor potential cation channels.” Am J Physiol Cell Physiol. 2015;308(11): c867-8.
- 10. Yang K, Lu W, Jia J, Zhang J, Zhao M, Wang S, et al. Noggin inhibits hypoxia-induced proliferation by targeting store-operated calcium entry and transient receptor potential cation channels. Am J Physiol Cell Physiol. 2015;308(11):C869-78.
- 11. Smith WC, Harland RM. Expression cloning of noggin, a new dorsalizing factor localized to the Spemann organizer in Xenopus embryos. Cell. 1992;70(5):829-40.
- 12. Avsian-Kretchmer O, Hsueh AJW. Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists. Mol Endocrinol. 2004;18(1):1-12.
- 13. Krause C, Guzman A, Knaus P. Noggin. Int J Biochem Cell Biol. 2011;43(4):478-81.
- 14. Tylzanowski P, Mebis L, Luyte FP. The Noggin null mouse phenotype is strain dependent and haploinsufficieny leads to skeletal defects. Developmental Dynamics. 2006;235(6):1599-607.
- 15. Marcelino J, Sciortino cm, Romero MF, Ulatowski LM, Ballock RT. Economides A. N., et al. Human disease-causing NOG missense mutations: effects on noggin secretion, dimer formation, and bone morphogenetic protein binding. Proc Natl Acad Sci USA. 2001; 98(20):11353-8.
- 16. Masuda S, Namba K, Mutai H, Usui S, Miyanaga Y, Kaneko H, et al. A mutation in the heparin-binding site of noggin as a novel mechanism of proximal symphalangism and conductive hearing loss. Biochem Biophys Res Commun. 2014;447(3):496-502.
- 17. Wang G, Zhang H, Zhao Y, Li J, Cai J, Wang P, et al. Noggin and bFGF cooperate to maintain the pluripotency of human embryonic stem cells in the absence of feeder layers. Biochem Biophys Res Commun. 2005;330(3):934-42.
- 18. Schwaninger R, Rentsch CA, Wetterwald A, van der Horst G, van Bezooijen RL, van der Pluijm G, et al. Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. Am J Pathol. 2007;170(1):160-75.
- 19. Lin SJ, Lerch TF, Cook RW, Jardetzky TS, Woodruff TK. The structural basis of TGF-beta, bone morphogenetic protein, and activin ligand binding. Reproduction. 2006;132(2):179-90.
- 20. Gerhart J, Pfautz J, Neely C, Elder J, DuPrey K, Menko AS, et al.: Noggin producing, MyoD-positive cells are crucial for eye development. Dev. Biol. 2009;336(1):30-41.
- 21. Sharov AA, Weiner L, Sharova TY, Siebenhaar F, Atoyan R, Reginato AM, et al.: Noggin overexpression inhibits eyelid opening by altering epidermal apoptosis and differentiation. EMBO J. 2003;22(12):2992-3003.
- 22. Lim DA, Tramontin AD, Trevejo JM, Herrera DG, García-Verdugo JM, Alvarez-Buylla A. Noggin antagonizes BMP signaling to create a niche for adult neurogenesis. Neuron. 2000;28(3):713-26.
- 23. Stafford DA, Monica SD, Harland RM. Follistatin interacts with Noggin in the development of the axial skeleton. Mech Dev. 2014; 131(1):78-85.
- 24. Bonaguidi MA, Peng CY, McGuire T, Falciglia G, Gobeske KT, Czeisler C, et al. Noggin expands neural stem cells in the adult hippocampus. J Neurosci. 2008;28(37):9194-204.
- 25. Grenier-Vallée P. Noggin and Chordin knockdown in Distraction Osteogenesis. Canada: M. Sc. Thesis, Univ. McGill. 2013:101 pp. Available from: http://http://digitool.library.mcgill.ca/thesisfile116968.pdf.
- 26. Freedman DS, Horlick M, Berenson GS. A comparison of the Slaughter skinfold-thickness equations and BMI in predicting body fatness and cardiovascular disease risk factor levels in children1-4. Am J Clin Nutr. 2013;98(6):1417-24.
- 27. Rothberg AE, McEwen LN, Kraftson AT, Ajluni N, Fowler CE, Nay CK, et al. Impact of weight loss on waist circumference and the components of the metabolic syndrome. BMJ Open Diabetes Res Care. 2017;5(1):e000341.
- 28. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al.: 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37(1):67-119.
- 29. Alhabeeb W, Idrees MM, Ghio S, Kashour T. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension due to left heart disease. Ann Thorac Med. 2014;9(1):S47-S55.
- 30. McNeil K, Dunning J, Morrell NW. The pulmonary physician in critical care. 13: The pulmonary circulation and right ventricular failure in the ITU. Thorax. 2003;58(2):157-62.
- 31. Jernigan NL, Resta TC. Calcium homeostasis and sensitization in pulmonary arterial smooth muscle. Microcirculation. 2014;21(3):259-71.
- 32. La Rosa I, Camargo LSA, Pereira MM, Fernandez-Martin R, Paz DA. Effects of bone morphogenic protein 4 (BMP4) and its inhibitor, Noggin, on in vitro maturation and culture of bovine preimplantation embryos. Reprod Biol Endocrinol. 2011;9:18.
- 33. Wright AF. The Influence of Gender and Sex Hormones in the Development of Translational and Experimental Pulmonary Arterial Hypertension. United Kingdom, Scotland: Ph. D. Thesis, Univ. Glasgow 2014:302 pp.
- 34. White K, Johansen AK, Nilsen M, Ciuclan L, Wallace E, Paton, L, et al. Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension. Circulation. 2012;126(9):1087-98.
- 35. Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP, et al. Alterations in oestrogen metabolism: Implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J. 2009;34(5),1093-9.
- 36. Mitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, et al. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension. 2004;43:1239-45.
- 37. Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age and gender-related ventricular-vascular stiffening: A community-based study. Circulation. 2005;112(15):2254-62.
- 38. Sun Z. Aging, arterial stiffness, and hypertension. Hypertension. 2015;65(2):252-6.
- 39. Berra G, Noble S, Soccal PM, Beghetti M, Lador F. Pulmonary hypertension in the elderly: a different disease? Breathe (Sheff). 2016;12(1):43-9.
- 40. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducoloné A, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(2):189-94.
- 41. Moreira EM, Gall H, Leening MJG, Lahousse L, Loth DW, Krijthe BP, et al. Prevalence of pulmonary hypertension in the general population: The Rotterdam study. PLoS One. 2015;10 (6):e0130072.
- 42. Zhao L, Wang J, Wang L, Liang YT, Chen YQ, Lu WJ, et al. Remodeling of rat pulmonary artery induced by chronic smoking exposure. J Thorac Dis. 2014;6(6):818-28.
- 43. Archer A, Weir E, Wilkins M. The Basic Science of pulmonary arterial hypertension for clinicians: new concepts and experiemntal therapies. Circulation. 2010;121(18):2045-66.
- 44. Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, Ducoloné A, Ehrhart, M, et al. “Natural history” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med. 2001;164(2):219-24.
- 45. Scharf SM, Iqbal M, Keller C, Criner G, Lee S, et al. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med. 2002;166(3):314-22.
- 46. Floyd R, Wray S. Calcium transporters and signalling in smooth muscles. Cell Calcium. 2007;42(4-5):467-76.
- 47. Lu W, Ran P, Zhang D, Lai N, Zhong N, Wang J. Bone morphogenetic protein 4 enhances canonical transient receptor potential expression, store-operated Ca2+ entry, and basal [Ca2+]i in rat distal pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol. 2010;299(6): C1370-78.
- 48. Ashwell M, Gibson S. Waist-to-height ratio as an indicator of early health risk: Simpler and more predictive than using a matrix based on BMI and waist circumference. BMJ Open. 2016;6(3):e010159.
- 49. Hammod HJ, Al-Dujaili AN, Al-Dujaili MN. Relationship between adipocyte fatty acid-binding protein in obese men with cardiovascular diseases. Res J Pharm Biol Chem Sci. 2016;7(3):804-8.
- 50. Hammod HJ, Al-Dujaili AN, Al-Dujaili MN. The Correlation between cardiovascular diseases in obese men with the inflammatory markers: Dyslipidemia, C-reactive protein and tumor necrosis factor-α. Res J Pharm Biol Chem Sci. 2016;7(3):809-14.
- 51. Taichman DB, Mandel J. Epidemiology of pulmonary arterial hypertension. Clin Chest Med. 2007;28(1):1-22.
- 52. Burger CD, Foreman AJ, Miller DP, Safford RE, McGoon MD, Badesch DB. Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term PAH disease management with normative values from the national health and nutrition examination survey. Mayo Clin Proc. 2011;86(2):105-12.
- 53. Leone N, Courbon D, Thomas F, Bean K, Jego B, Leynaert B, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med. 2009;179(6):509-16.
- 54. Taraseviciute A, Voelkel NF. Severe pulmonary hypertension in postmenopausal obese women. Eur J Med Res. 2006;11(5):198-202.
- 55. Zeng W, Sun Y, Gu Q, Xiong C, Li J, He J. The impact of pulmonary arterial hypertension-targeted therapy on survival in Chinese patients with idiopathic pulmonary arterial hypertension. Pulm Circ. 2012;2(3):373-8.